Table 2.
Outcome of Kaposi sarcoma patients with IRIS and non-IRIS; treated with chemotherapy or without it, at time of last follow-up
| IRIS-KS (N = 35) | Non-IRIS-KS (N = 54) | Total (N = 89) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CR | PR | Death | CR | PR | Death | CR | PR | Death | |
| Chemotherapy—N (%) | 19 (54) | 3 (9)a | 9 (26) | 15 (28) | 0 | 2 (4) | 34 (38) | 3 (3) | 11 (12) |
| No-chemotherapy N (%) | 4 (11) | 0 | 0 | 33 (61) | 1 (2) | 3 (5) | 37 (42) | 1 (1) | 3 (3) |
| Total, N (%) | 23 (65) | 3 (9) | 9 (26) | 48 (89) | 1 (2) | 5 (9) | 71 (80) | 4 (4) | 14 (16) |
IRIS-KS immune reconstitution inflammatory syndrome-Kaposi’s sarcoma, CR complete response, PR partial response
aOne patient abandoned treatment, had Kaposi’s sarcoma progression and died with AIDS and related comorbidities